Nanovibronix Stock Today

NAOV Stock  USD 0.44  0.03  6.38%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

About Average

 
High
 
Low
NanoVibronix is selling for under 0.44 as of the 16th of February 2025; that is 6.38 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.42. NanoVibronix has 46 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 17th of January 2025 and ending today, the 16th of February 2025. Click here to learn more.
Business Domain
Health Care Equipment & Services
IPO Date
27th of June 2017
Category
Healthcare
Classification
Health Care
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York. The company has 6.14 M outstanding shares of which 1.66 M shares are now shorted by private and institutional investors with about 0.19 trading days to cover. More on NanoVibronix

Moving against NanoVibronix Stock

  0.83ANGO AngioDynamicsPairCorr
  0.72IRMD IradimedPairCorr
  0.69NPCE NeuropacePairCorr
  0.65DRTS Alpha Tau MedicalPairCorr
  0.63ELMD ElectromedPairCorr
  0.56A Agilent TechnologiesPairCorr

NanoVibronix Stock Highlights

CEO, DirectorBrian Murphy
Thematic IdeaMedical Equipment (View all Themes)
Business ConcentrationHealth Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Medical Equipment, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors)
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.250.39
Way Down
Pretty Stable
Gross Profit Margin0.610.77
Significantly Down
Slightly volatile
Total Current Liabilities1.8 M2.8 M
Way Down
Slightly volatile
Non Current Liabilities Total198.4 K208.8 K
Notably Down
Slightly volatile
Total Assets8.1 M7.7 M
Sufficiently Up
Slightly volatile
Total Current Assets7.8 M7.5 M
Sufficiently Up
Slightly volatile
Debt Levels
NanoVibronix can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand NanoVibronix's financial leverage. It provides some insight into what part of NanoVibronix's total assets is financed by creditors.
Liquidity
NanoVibronix currently holds 5 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. NanoVibronix has a current ratio of 3.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about NanoVibronix's use of debt, we should always consider it together with its cash and equity.

Capital Expenditures

855
NanoVibronix (NAOV) is traded on NASDAQ Exchange in USA. It is located in 525 Executive Boulevard, Elmsford, NY, United States, 10523 and employs 10 people. NanoVibronix is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.7 M. NanoVibronix conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 6.14 M outstanding shares of which 1.66 M shares are now shorted by private and institutional investors with about 0.19 trading days to cover. NanoVibronix currently holds about 3.94 M in cash with (3.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.14.
Check NanoVibronix Probability Of Bankruptcy
Ownership Allocation
Roughly 90.84 % of NanoVibronix outstanding shares are held by general public with 0.12 pct. owned by insiders and only 9.04 % by institutional investors.
Check NanoVibronix Ownership Details

NanoVibronix Stock Institutional Holders

InstituionRecorded OnShares
Armistice Capital, Llc2024-09-30
278.7 K
Vanguard Group Inc2024-09-30
30.2 K
Renaissance Technologies Corp2024-09-30
26.6 K
Citadel Advisors Llc2024-09-30
23.8 K
Geode Capital Management, Llc2024-09-30
22.8 K
Two Sigma Securities, Llc2024-09-30
21.2 K
Tower Research Capital Llc2024-09-30
6.1 K
Ubs Group Ag2024-09-30
1.5 K
Bank Of America Corp2024-09-30
24.0
View NanoVibronix Diagnostics

NanoVibronix Historical Income Statement

At this time, NanoVibronix's Depreciation And Amortization is fairly stable compared to the past year. Total Revenue is likely to climb to about 2.8 M in 2025, whereas Selling General Administrative is likely to drop slightly above 2.4 M in 2025. View More Fundamentals

NanoVibronix Stock Against Markets

NanoVibronix Corporate Management

Additional Tools for NanoVibronix Stock Analysis

When running NanoVibronix's price analysis, check to measure NanoVibronix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NanoVibronix is operating at the current time. Most of NanoVibronix's value examination focuses on studying past and present price action to predict the probability of NanoVibronix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NanoVibronix's price. Additionally, you may evaluate how the addition of NanoVibronix to your portfolios can decrease your overall portfolio volatility.